Lamivudin Aurobindo (Lamivudine)

Lamivudine is a nucleoside analogue that mimics natural nucleotides. It is incorporated into viral DNA by reverse transcriptase, lacking a 3'-hydroxyl group, which halts DNA chain elongation and prevents the virus from replicating its genome.

The specific dose of Lamivudin Aurobindo is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and treatment guidelines. Only a qualified healthcare professional should set the dosing regimen.

Safety data for lamivudine in pregnancy are limited, and the medication should only be used if the potential benefit justifies any potential risk to the fetus. Breastfeeding decisions should be made with a healthcare provider, as lamivudine can be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lamivudine is a nucleoside reverse transcriptase inhibitor, often used in combination regimens. Compared with other NRTIs, it has a favorable safety profile and low pill burden, but resistance can develop if used as monotherapy. Clinicians typically combine it with drugs from other classes for optimal viral suppression.

Lamivudin Aurobindo tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

The medication is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water. Patients should follow the dosing schedule precisely to maintain effective drug levels.

Serious adverse events include lactic acidosis, severe hepatotoxicity, Stevens‑Johnson syndrome, and pancreatitis. Patients should be monitored for unexplained fatigue, abdominal pain, jaundice, rash, or signs of pancreatic inflammation, and seek immediate medical attention if these occur.

Lamivudin Aurobindo should be avoided in individuals with known hypersensitivity to lamivudine or any of the tablet excipients. Caution is also advised for patients with severe hepatic or renal impairment, and it is not recommended for use in patients with active, severe mitochondrial disease.